Aileron Therapeutics Inc (NAS:ALRN)

$ 2.87 0.03 (1.06%) Market Cap: 61.96 Mil Enterprise Value: 44.70 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 42/100

Aileron Therapeutics Inc M&A Call Transcript
Oct 31, 2023
Aileron Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual)- Pre-recorded Transcript
Sep 12, 2022
Aileron Therapeutics Inc Phase 1b Non-Small Cell Lung Cancer Interim Analysis Conference Call Transcript
Jun 29, 2022
Aileron Therapeutics Inc at Emerging Growth Conference Transcript
Jan 05, 2022
Aileron Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Q3 2019 Aileron Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

$10.4 (-7.70%)

Earnings

Aileron Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript

Jul 15, 2021 / 07:00PM GMT

Release Date Price: $21.4 (-1.83%)

Transcript

Matt Phipps

William Blair & Company, L.L.C. - Analyst

Hello, everyone. My name is Matt Phipps, biotech analyst here at William Blair. Thanks for joining us for another fireside chat. In this one, I am happy to have Manuel Aivado, the CEO of Aileron Therapeutics, talk about the Company's unique approach to providing better outcomes for oncology patients and a unique modality that we will get into. Manny will start with a few slides to provide background, and then we will have a Q&A discussion. So Manuel, thanks for being here.

Manuel Aivado

Aileron Therapeutics, Inc. - President & CEO

Thank you, Matt, and good afternoon, everyone. It is my sincere pleasure to be speaking at this event. Thanks for the invite. I will start us off with a brief presentation in which I will be making forward-looking statements as outlined on our slide here.

And if the Company had to be summarized in only one slide, here is what you would see. We are developing a chemoprotection drug called ALRN-6924. With the recent FDA approval of COSELA by G1 Therapeutics,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.